Last reviewed · How we verify

DPP-IV Inhibitor

Hoffmann-La Roche · Phase 2 active Small molecule

DPP-IV inhibitors block the action of dipeptidyl peptidase-4, an enzyme that breaks down incretin hormones, thereby increasing incretin levels and enhancing glucose-dependent insulin secretion.

DPP-IV inhibitors block the action of dipeptidyl peptidase-4, an enzyme that breaks down incretin hormones, thereby increasing incretin levels and enhancing glucose-dependent insulin secretion. Used for Type 2 diabetes.

At a glance

Generic nameDPP-IV Inhibitor
SponsorHoffmann-La Roche
Drug classDPP-IV inhibitor
TargetDPP-4
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 2

Mechanism of action

This leads to increased insulin secretion in response to meals and decreased glucagon secretion. The increased incretin levels also enhance the release of insulin from the pancreas in response to meals, thereby lowering blood glucose levels.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: